产品
编 号：F200921
分子式：C20H21F3N4O
分子量：390.4
分子式：C20H21F3N4O
分子量：390.4
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
5mg
360
In-stock
10mg
600
In-stock
25mg
1200
In-stock
50mg
1920
In-stock
100mg
3040
In-stock
结构图
CAS No: 167933-07-5
产品详情
生物活性：
Flibanserin (BIMT-17; BIMT-17BS) is an orally active serotonin 5-HT1A receptor agonist and 5-HT2A receptor antagonist with Ki values of 1 nM and 49 nM, respectively. Flibanserin binds to dopamine D4 receptors with an Ki value of 4-24 nM. Flibanserin shows anti-depression and anti-anxiety effect, can be used to hypoactive sexual desire disorder (HSDD) research-.
体内研究：
Flibanserin (1, 10, 30 mg/kg; i.p.; single dose) shows different pharmacological properties in prefrontal cortex, hippocampus and midbrain. The 5-HT1A receptor occupancy in cortex indicates it’s the more sensitive than other brain region.Flibanserin (15, 45 mg/kg; p.o.; twice a day; 22 d) preferentially activates the brain regions belonging to the mesolimbic dopaminergic pathway and hypothalamic structures involved in the integration of sexual cues related to sexual motivation.Flibanserin (5, 10, 25, and 50 mg/kg; s.c.; single dose) has anxiolytic effects without locomotor side effects in rat ultrasonic vocalization model.Animal Model:Long Evans female rats (225-250 g)
Dosage:15 mg/kg; 45 mg/kg
Administration:Oral gavage; twice a day for 22 days
Result:Increased the density of activated catecholaminergic neurons in the ventral tegmental area but not in the locus coeruleus.Increased Fos expression in the medial preoptic area and arcuate nucleus of the hypothalamus, ventral tegmental area, locus coeruleus, and lateral paragigantocellular nucleus with chronic 22-day treatment.
Animal Model:Rat pup ultrasonic vocalization model of anxiety
Dosage:5, 10, 25, and 50 mg/kg
Administration:Subcutaneous injection
Result:Reduced ultrasonic vocalizations in rat pups.Showed effective within 30 min and has no severe locomotor side effects at active doses.
体外研究：
Flibanserin (0.01-100 μM; 72 h) can transform into two degradation products DP1 and DP2 with no toxicity potential after oxidative degradation.
Flibanserin (BIMT-17; BIMT-17BS) is an orally active serotonin 5-HT1A receptor agonist and 5-HT2A receptor antagonist with Ki values of 1 nM and 49 nM, respectively. Flibanserin binds to dopamine D4 receptors with an Ki value of 4-24 nM. Flibanserin shows anti-depression and anti-anxiety effect, can be used to hypoactive sexual desire disorder (HSDD) research-.
体内研究：
Flibanserin (1, 10, 30 mg/kg; i.p.; single dose) shows different pharmacological properties in prefrontal cortex, hippocampus and midbrain. The 5-HT1A receptor occupancy in cortex indicates it’s the more sensitive than other brain region.Flibanserin (15, 45 mg/kg; p.o.; twice a day; 22 d) preferentially activates the brain regions belonging to the mesolimbic dopaminergic pathway and hypothalamic structures involved in the integration of sexual cues related to sexual motivation.Flibanserin (5, 10, 25, and 50 mg/kg; s.c.; single dose) has anxiolytic effects without locomotor side effects in rat ultrasonic vocalization model.Animal Model:Long Evans female rats (225-250 g)
Dosage:15 mg/kg; 45 mg/kg
Administration:Oral gavage; twice a day for 22 days
Result:Increased the density of activated catecholaminergic neurons in the ventral tegmental area but not in the locus coeruleus.Increased Fos expression in the medial preoptic area and arcuate nucleus of the hypothalamus, ventral tegmental area, locus coeruleus, and lateral paragigantocellular nucleus with chronic 22-day treatment.
Animal Model:Rat pup ultrasonic vocalization model of anxiety
Dosage:5, 10, 25, and 50 mg/kg
Administration:Subcutaneous injection
Result:Reduced ultrasonic vocalizations in rat pups.Showed effective within 30 min and has no severe locomotor side effects at active doses.
体外研究：
Flibanserin (0.01-100 μM; 72 h) can transform into two degradation products DP1 and DP2 with no toxicity potential after oxidative degradation.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备